-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 4,168 Shares of Stock
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 4,168 Shares of Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 4,168 shares of the firm's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the sale, the insider now owns 100,598 shares in the company, valued at $2,113,563.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Crinetics Pharmaceuticals Stock Performance
NASDAQ:CRNX opened at $20.27 on Tuesday. The company has a 50-day moving average of $20.63 and a 200-day moving average of $20.13. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.87 and a beta of 1.20. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.91 and a 52 week high of $28.95.
Get Crinetics Pharmaceuticals alerts:Hedge Funds Weigh In On Crinetics Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in Crinetics Pharmaceuticals by 70.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares during the last quarter. Dupont Capital Management Corp lifted its holdings in Crinetics Pharmaceuticals by 36.3% during the 2nd quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares during the last quarter. Group One Trading L.P. lifted its holdings in Crinetics Pharmaceuticals by 31.6% during the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Crinetics Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $188,000. 94.42% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, SVB Leerink raised their price target on shares of Crinetics Pharmaceuticals from $36.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday, May 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $39.67.Crinetics Pharmaceuticals Company Profile
(Get Rating)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Stories
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 4,168 shares of the firm's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the sale, the insider now owns 100,598 shares in the company, valued at $2,113,563.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
CRinetics製藥公司(納斯達克代碼:CRNX-GET Rating)內部人士斯蒂芬·F·貝茨在9月15日(星期四)的一筆交易中出售了4,168股該公司股票。該股以21.01美元的平均價格出售,總成交金額為87,569.68美元。出售完成後,這位內部人士現在擁有該公司100,598股,價值2,113,563.98美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個超級鏈接獲得。
Crinetics Pharmaceuticals Stock Performance
Crinetics製藥類股表現
NASDAQ:CRNX opened at $20.27 on Tuesday. The company has a 50-day moving average of $20.63 and a 200-day moving average of $20.13. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.87 and a beta of 1.20. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.91 and a 52 week high of $28.95.
納斯達克:CRNX週二開盤報20.27美元。該公司的50日移動均線切入位在20.63美元,200日移動均線切入位在20.13美元。該公司市值為10.9億美元,市盈率為-6.87倍,貝塔係數為1.20。Crinetics PharmPharmticals,Inc.的52周低點為15.91美元,52周高位為28.95美元。
Hedge Funds Weigh In On Crinetics Pharmaceuticals
對衝基金買入Crinetics製藥公司
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in Crinetics Pharmaceuticals by 70.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares during the last quarter. Dupont Capital Management Corp lifted its holdings in Crinetics Pharmaceuticals by 36.3% during the 2nd quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares during the last quarter. Group One Trading L.P. lifted its holdings in Crinetics Pharmaceuticals by 31.6% during the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Crinetics Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $188,000. 94.42% of the stock is owned by institutional investors.
對衝基金和其他機構投資者最近對他們在該業務中的頭寸進行了調整。Cubist System Strategy LLC在第二季度將其在Crinetics PharmPharmticals的持股增加了70.4%。Cubist Systems Strategy LLC在上個季度額外購買了3503股後,現在擁有8,478股該公司股票,價值15.8萬美元。杜邦資本管理公司(DuPont Capital Management Corp)在第二季度增持了36.3%的Crinetics PharmPharmticals股份。杜邦資本管理公司(DuPont Capital Management Corp)目前持有8,629股該公司股票,價值161,000美元,此前該公司在上個季度又購買了2,297股。Group one Trading L.P.在第一季度增持了Crinetics PharmPharmticals 31.6%的股份。Group One Trading L.P.現在持有該公司7318股股票,價值16.1萬美元,在上個季度又購買了1759股。蘇黎世廣東銀行第一季度增持Crinetics PharmPharmticals股份17.4%。Zurcher Kantonalbank蘇黎世廣東銀行在上個季度額外購買了1110股後,現在擁有7493股該公司股票,價值16.4萬美元。最後,亞利桑那州退休系統在第二季度購買了Crinetics製藥公司的一個新頭寸,價值約為188,000美元。94.42%的股票由機構投資者持有。
Analysts Set New Price Targets
分析師設定新的價格目標
Crinetics Pharmaceuticals Company Profile
Crinetics製藥公司簡介
(Get Rating)
(獲取評級)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Crinetics製藥公司是一家臨牀階段製藥公司,專注於罕見內分泌疾病和內分泌相關腫瘤治療藥物的發現、開發和商業化。它的主要候選產品是Paltusotine,這是一種口服選擇性非肽生長抑素受體2型激動劑,已經完成了治療肢端肥大症的第三階段臨牀試驗,以及治療類癌綜合徵和無功能神經內分泌腫瘤(NETS)的第二階段臨牀試驗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免費獲取StockNews.com的Crinetics PharmPharmticals研究報告(CRNX)
- 甲骨文的短期痛苦可能是你的長期收益
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它:投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎?
- 自動區重新進入拉力賽模式,新高在望
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Crinetics PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Crinetics製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧